236 related articles for article (PubMed ID: 15468763)
1. Three-stage sequential statistical dissolution testing rules.
Tsong Y; Shen M; Shah VP
J Biopharm Stat; 2004 Aug; 14(3):757-79. PubMed ID: 15468763
[TBL] [Abstract][Full Text] [Related]
2. Dissolution test acceptance sampling plans.
Tsong Y; Hammerstrom T; Lin K; Ong TE
J Biopharm Stat; 1995 Jul; 5(2):171-83. PubMed ID: 7581426
[TBL] [Abstract][Full Text] [Related]
3. Parametric two-stage sequential quality assurance test of dose content uniformity.
Tsong Y; Shen M
J Biopharm Stat; 2007; 17(1):143-57. PubMed ID: 17219760
[TBL] [Abstract][Full Text] [Related]
4. An inferential procedure for the probability of passing the USP dissolution test.
Chiang C; Chen CF; Huang MY; Liu JP
Pharm Stat; 2012; 11(1):32-8. PubMed ID: 21506255
[TBL] [Abstract][Full Text] [Related]
5. Probability of passing dissolution acceptance criteria for an immediate release tablet.
Dumont ML; Berry MR; Nickerson B
J Pharm Biomed Anal; 2007 May; 44(1):79-84. PubMed ID: 17379465
[TBL] [Abstract][Full Text] [Related]
6. Estimation of the probability of passing the USP dissolution test.
Wang H
J Biopharm Stat; 2007; 17(3):407-13. PubMed ID: 17479390
[TBL] [Abstract][Full Text] [Related]
7. Statistical comparison between dissolution profiles of drug products.
Chow SC; Ki FY
J Biopharm Stat; 1997 May; 7(2):241-58. PubMed ID: 9136067
[TBL] [Abstract][Full Text] [Related]
8. The USP Performance Verification Test, Part I: USP Lot P Prednisone Tablets: quality attributes and experimental variables contributing to dissolution variance.
Deng G; Ashley AJ; Brown WE; Eaton JW; Hauck WW; Kikwai LC; Liddell MR; Manning RG; Munoz JM; Nithyanandan P; Glasgow MJ; Stippler E; Wahab SZ; Williams RL
Pharm Res; 2008 May; 25(5):1100-9. PubMed ID: 18172581
[TBL] [Abstract][Full Text] [Related]
9. A mini review of scientific and pharmacopeial requirements for the disintegration test.
Donauer N; Löbenberg R
Int J Pharm; 2007 Dec; 345(1-2):2-8. PubMed ID: 17935916
[TBL] [Abstract][Full Text] [Related]
10. Official USP Reference Standards: metrology concepts, overview, and scientific issues and opportunities.
Williams RL; ;
J Pharm Biomed Anal; 2006 Jan; 40(1):3-15. PubMed ID: 16303277
[TBL] [Abstract][Full Text] [Related]
11. Hydrodynamic investigation of USP dissolution test apparatus II.
Bai G; Armenante PM; Plank RV; Gentzler M; Ford K; Harmon P
J Pharm Sci; 2007 Sep; 96(9):2327-49. PubMed ID: 17573698
[TBL] [Abstract][Full Text] [Related]
12. In vivo/in vitro correlations for four differently dissolving ketorolac tablets.
Gordon MS; Chowhan Z
Biopharm Drug Dispos; 1996 Aug; 17(6):481-92. PubMed ID: 8866039
[TBL] [Abstract][Full Text] [Related]
13. The USP Performance Verification Test, Part II: collaborative study of USP's Lot P Prednisone Tablets.
Glasgow M; Dressman S; Brown W; Foster T; Schuber S; Manning RG; Wahab SZ; Williams RL; Hauck WW
Pharm Res; 2008 May; 25(5):1110-5. PubMed ID: 18172582
[TBL] [Abstract][Full Text] [Related]
14. Hydrodynamics-induced variability in the USP apparatus II dissolution test.
Baxter JL; Kukura J; Muzzio FJ
Int J Pharm; 2005 Mar; 292(1-2):17-28. PubMed ID: 15725550
[TBL] [Abstract][Full Text] [Related]
15. Shear distribution and variability in the USP Apparatus 2 under turbulent conditions.
Kukura J; Baxter JL; Muzzio FJ
Int J Pharm; 2004 Jul; 279(1-2):9-17. PubMed ID: 15234789
[TBL] [Abstract][Full Text] [Related]
16. Statistical properties of the USP dissolution test with pooled samples.
Saccone CD; Meneces NS; Tessore J
PDA J Pharm Sci Technol; 2005; 59(5):310-9. PubMed ID: 16316066
[TBL] [Abstract][Full Text] [Related]
17. Discriminatory dissolution method for quality control measurements of carbamazepine immediate release tablets based on in vitro--in vivo investigations.
Xu C; Zou M; Wang Y; Liu Y; Yan J; Wu Y; Cheng G
Drug Dev Ind Pharm; 2012 Jun; 38(6):679-88. PubMed ID: 21988132
[TBL] [Abstract][Full Text] [Related]
18. Dissolution testing of orally disintegrating tablets.
Kraemer J; Gajendran J; Guillot A; Schichtel J; Tuereli A
J Pharm Pharmacol; 2012 Jul; 64(7):911-8. PubMed ID: 22686339
[TBL] [Abstract][Full Text] [Related]
19. Typical variability in drug dissolution testing: study with USP and FDA calibrator tablets and a marketed drug (glibenclamide) product.
Qureshi SA; McGilveray IJ
Eur J Pharm Sci; 1999 Feb; 7(3):249-58. PubMed ID: 9845813
[TBL] [Abstract][Full Text] [Related]
20. Probability lower bounds for USP/NF tests.
Chow SC; Shao J; Wang H
J Biopharm Stat; 2002 Feb; 12(1):79-92. PubMed ID: 12146721
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
